International Multi-center Comparative Randomized Double-blind Clinical Trial of Efficacy and Safety of BCD-057 (Adalimumab Produced by BIOCAD, Russia) and Humira (Adalimumab Produced by Vetter Pharma-Fertigung Gmbh & Co KG, Germany) in Patients With Moderate to Severe Plaque Psoriasis
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms CALYPSO
- Sponsors Biocad
- 06 Sep 2021 Status changed from active, no longer recruiting to completed.
- 06 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Apr 2017 New trial record